ImaginAb, MacroGenics Ink Deal for Companion Molecular Imaging Agents | GenomeWeb

NEW YORK (GenomeWeb News) – ImaginAb, a Los Angeles-based developer of molecular imaging agents, has entered into an alliance with MacroGenics to develop companion imaging agents for an anti-cancer drug being developed by the Rockville, Md.-based biotech firm.

Under the deal announced today, ImaginAb will develop companion imaging agents for B7-H3, an immune regulator target for which MacroGenics is developing therapeutics. It also is developing a clinical imaging strategy based on a Macrogenics anti-CD3 antibody as a patient selection tool for ongoing clinical programs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.